Review: Allogeneic HCT to Treat High-Risk Multiple Myeloma

In this review, the authors outline the use of allogeneic hematopoietic cell transplantation (HCT) to treat multiple myeloma (MM), noting that allogeneic HCT should be strongly considered only for high-risk MM patients as part of their initial course of therapy or in first chemotherapy-sensitive relapse within a clinical trial. They note that despite progress in survival with the availability of novel agents, an overwhelming majority of patients with multiple myeloma (MM) relapse, and that allogeneic HCT is a potentially curative option that has several advantages including a tumor-free graft, and the potential for sustained immune-mediated disease control. The authors note that allogeneic HCT can have a high treatment-related mortality (TRM), but that “newer preparative regimens, planned maintenance strategies and improvements in supportive care have led to a decline in TRM and better survival in recent years.”

Dhakal B, et al. Bone Marrow Transplant

Related Resource